MedTrace Logo

Nonablative Fractional Diode Laser for Treatment of Skin Resurfacing and Pigmented Lesions

NCT04203745 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2023-08-01

Study results available
· View outcomes & findings →

Summary

This study is intended to evaluate the efficacy and safety of a new diode fractional laser for skin resurfacing and treatment of pigmented lesions.

Conditions

  • Skin Texture
  • Pigmented Lesions

Interventions

DEVICE

Nonablative Fractional Diode Laser

The FRAX 1940 is a fractional 1940 nm solid-state diode laser that delivers linear arrays of microbeams to create nonablative microscopic treatment zones (MTZs) in the skin.

Sponsors & Collaborators

  • Candela Corporation

    lead INDUSTRY

Principal Investigators

  • Konika P Schallen, M.D. · Candela Corporation

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-09-18
Primary Completion
2021-04-30
Completion
2021-08-05
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04203745 on ClinicalTrials.gov